Form 4: Fortress Biotech CEO Sells $37,417 Worth of Series A Preferred Stock
SEC Form 4
Fortress Biotech's CEO, Lindsay A. Rosenwald, sold 5,000 shares of Series A Cumulative Perpetual Preferred Stock at an average price of $7.4835 on July 11, 2024.
Summary
- On July 11, 2024, Lindsay A. Rosenwald, the President, CEO, and Chairman of Fortress Biotech, Inc., sold 5,000 shares of Series A Cumulative Perpetual Preferred Stock.
- The sale was executed at a weighted average price of $7.4835 per share.
- The total value of the shares sold was approximately $37,417.
- Following the transaction, Rosenwald directly owns 127,500 shares of the Series A Cumulative Perpetual Preferred Stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of an insider transaction. The sentiment is neither positive nor negative as it simply reports a sale of shares.
Industry Context
This filing is a routine disclosure of insider trading activity. It provides transparency into the actions of company executives and their holdings in the company's stock.
Stakeholder Impact
- The sale of shares by the CEO could be perceived negatively by some shareholders, but it is a relatively small transaction and may not have a significant impact.
Key Dates
| Date | Description |
|---|---|
| 07/11/2024 | Date of the transaction: Lindsay A. Rosenwald sold shares of Series A Cumulative Perpetual Preferred Stock. |
| 07/15/2024 | Date of signature by Samuel Berry, Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.